- Home
- ARBE vs DSGN Comparison
ARBE vs DSGN Comparison
Compare ARBE & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBE
- DSGN
- Stock Information
- Founded
- ARBE 2015
- DSGN 2017
- Country
- ARBE Israel
- DSGN United States
- Employees
- ARBE N/A
- DSGN N/A
- Industry
- ARBE EDP Services
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ARBE Technology
- DSGN Health Care
- Exchange
- ARBE Nasdaq
- DSGN Nasdaq
- Market Cap
- ARBE 203.2M
- DSGN 208.9M
- IPO Year
- ARBE N/A
- DSGN 2021
- Fundamental
- Price
- ARBE $1.34
- DSGN $6.03
- Analyst Decision
- ARBE Buy
- DSGN
- Analyst Count
- ARBE 2
- DSGN 0
- Target Price
- ARBE $1.75
- DSGN N/A
- AVG Volume (30 Days)
- ARBE 1.1M
- DSGN 171.5K
- Earning Date
- ARBE 08-07-2025
- DSGN 11-06-2025
- Dividend Yield
- ARBE N/A
- DSGN N/A
- EPS Growth
- ARBE N/A
- DSGN N/A
- EPS
- ARBE N/A
- DSGN N/A
- Revenue
- ARBE $536,000.00
- DSGN N/A
- Revenue This Year
- ARBE $301.82
- DSGN N/A
- Revenue Next Year
- ARBE $250.52
- DSGN N/A
- P/E Ratio
- ARBE N/A
- DSGN N/A
- Revenue Growth
- ARBE N/A
- DSGN N/A
- 52 Week Low
- ARBE $0.85
- DSGN $2.60
- 52 Week High
- ARBE $5.09
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- ARBE 50.83
- DSGN 58.00
- Support Level
- ARBE $1.27
- DSGN $5.65
- Resistance Level
- ARBE $1.44
- DSGN $6.65
- Average True Range (ATR)
- ARBE 0.08
- DSGN 0.51
- MACD
- ARBE 0.02
- DSGN -0.00
- Stochastic Oscillator
- ARBE 52.00
- DSGN 64.27
About ARBE Arbe Robotics Ltd.
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.